Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis - 1 views
-
Padayatty and colleagues showed that high-level ascorbic acid plasma concentrations could only be achieved by intravenous administration
-
No patient in the low or high dose ascorbic acid treatment arms of this study suffered any identifiable adverse event
-
a pharmacologic ascorbic acid treatment strategy in critically ill patients with severe sepsis appears to be safe
- ...7 more annotations...
-
Ascorbic acid depletion in sepsis results from ascorbic acid consumption by the reduction of plasma free iron, ascorbic acid consumption by the scavenging of aqueous free radicals (peroxyl radicals), and by the destruction of the oxidized form of ascorbic acid dehydroascorbic acid
-
Sepsis further inhibits intracellular reduction of dehydroascorbic acid, producing acute intracellular ascorbic acid depletion
-
Ascorbic acid treated patients in this study exhibited rapid and sustained increases in plasma ascorbic acid levels using an intermittent every six hours administration protocol
-
Septic ascorbic acid-deficient neutrophils fail to undergo normal apoptosis. Rather, they undergo necrosis thereby releasing hydrolytic enzymes in tissue beds, thus contributing to organ injury
-
Repletion of ascorbic acid in this way allows for normal apoptosis, thus, preventing the release of organ damaging hydrolytic enzymes.
-
Study finds IV vitamin C in patients with sepsis is very safe and blunts the effects (endothelial damage, end organ damage...) of sepsis. Of note, the IV vitamin C group reached serum levels of ascorbic acid of 1,592 to 5,722 micromol/L. The IV groups maintained elevated serum C levels for up to 96 hours post infusion.